- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Immunotherapy Landscape in cSCC and BCC
Leading experts discuss the evolving role of immunotherapy and neoadjuvant therapies in cSCC and BCC treatment.
EP: 1.Prevalence of Cutaneous Squamous Cell Carcinoma (CSCC) & Basal Cell Carcinoma (BCC)
EP: 2.Immunotherapy Landscape in cSCC and BCC
EP: 3.Immunotherapy and Radiation Therapy in cSCC and BCC
EP: 4.Immunotherapy Barriers: Multidisciplinary Approach in cSCC and BCC
EP: 5.Coordination of Care: Interdisciplinary Immunotherapy Challenges in Nonmelanoma Skin Cancers
EP: 6.Multidisciplinary Collaboration: Best Practices for CSCC and BCC Management
EP: 7.Dermatologists and Immunotherapy: Managing Patient Expectations
EP: 8.Monitoring Immunotherapy Toxicities in CSCC and BCC
EP: 9.Staging Disease and Risk Stratification in CSCC and BCC
EP: 10.Targeted Therapy: Hedgehog Inhibitors in BCC
EP: 11.Socioeconomic Implications of CSCC and BCC
EP: 12.Immunosuppression in CSCC and BCC Treatment
EP: 13.Updates in Therapeutics for Nonmelanoma Skin Cancers
EP: 14.Concluding Thoughts on the Future of CSCC and BCC Care
This is a video synopsis/summary of a Peer Exchange involving Jason Luke, MD, FACP; Christopher Barker, MD; Omid Hamid, MD; Vishal Patel, MD; and Catherine Pisano, MD.
Patel explained that while most basal cell carcinomas (BCCs) and cutaneous squamous cell carcinomas (cSCCs) are treated surgically, a subset of patients with recurrent, advanced or metastatic disease require systemic therapy. He noted systemic treatment is also considered for some patients with a high disease burden for whom surgery would be excessively disfiguring or challenging. Luke highlighted the increasing use of immunotherapy in the neoadjuvant setting across cancer types to facilitate organ preservation and improve outcomes. Hamid discussed a neoadjuvant trial in cSCC that demonstrated high pathologic complete response rates and helped make previously unresectable tumors suitable for surgery. The discussants agreed that the impressive responses observed with neoadjuvant cemiplimab set the stage for testing shortened treatment courses and even nonsurgical management in some cSCC patients.
Video synopsis is AI-generated and reviewed by AJMC editorial staff.
EHA Plenary Abstracts Zoom in From Investigational Drugs to Molecular Signatures
June 14th 2025Abstracts presented during the plenary session of the 2025 European Hematology Association (EHA) Congress spanned from novel drug regimens for myeloma and lymphoma to investigation of leukemias on the molecular and genetic levels.
Read More
COVID-19 Deaths Cloud Interpretation of Acalabrutinib-Venetoclax Combo Results
June 13th 2025A combination of acalabrutinib and venetoclax showed better results with the addition of obinutuzumab, whereas mixed findings in a cross-trial comparison were complicated by the inclusion of deaths related to COVID-19.
Read More
Measurable Residual Disease in Decision-Making: An Opportunity, but Not a Promise
June 13th 2025Skepticism still persists around the use of measurable residual disease (MRD) for clinical and regulatory decision-making in the European context, but panelists explained the next steps that are required to advance the use of MRD.
Read More
